Fig. 2.

Inhibition of CDK7 impacts transcription and cell cycle progression in HER2+ breast cancer cells. a Cells were treated with vehicle control (DMSO) or THZ1 (100 nM) at 0, 3, 6, or 24 h before immunoblotting using the indicated antibodies. b, c Dose-response curves of viability of breast cancer cells after treatment with increasing concentrations of triptolide or purvalnolol for 72 h. Percent viability relative to that of DMSO-treated cells is shown. Data represent mean ± SD of replicates from two or three independent experiments